GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Manhattan Scientifics Inc (OTCPK:MHTX) » Definitions » Operating Income

Manhattan Scientifics (Manhattan Scientifics) Operating Income : $-0.71 Mil (TTM As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Manhattan Scientifics Operating Income?

Manhattan Scientifics's Operating Income for the three months ended in Mar. 2024 was $-0.19 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.71 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Manhattan Scientifics's Operating Income for the three months ended in Mar. 2024 was $-0.19 Mil. Manhattan Scientifics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Manhattan Scientifics's Operating Margin % for the quarter that ended in Mar. 2024 was %.

Manhattan Scientifics's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Manhattan Scientifics's annualized ROC % for the quarter that ended in Mar. 2024 was -358.88%. Manhattan Scientifics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.


Manhattan Scientifics Operating Income Historical Data

The historical data trend for Manhattan Scientifics's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Manhattan Scientifics Operating Income Chart

Manhattan Scientifics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.03 -0.68 -0.69 -0.68 -0.70

Manhattan Scientifics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.19 -0.18 -0.15 -0.19

Manhattan Scientifics Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Manhattan Scientifics  (OTCPK:MHTX) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Manhattan Scientifics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-0.768 * ( 1 - 0% )/( (0.317 + 0.111)/ 2 )
=-0.768/0.214
=-358.88 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Manhattan Scientifics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.768/( ( (0 + max(-2.056, 0)) + (0 + max(-2.206, 0)) )/ 2 )
=-0.768/( ( 0 + 0 )/ 2 )
=-0.768/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.002) - (2.048 + 0.01 + 0)
=-2.056

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.009) - (2.195 + 0.02 + 0)
=-2.206

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Manhattan Scientifics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-0.192/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Manhattan Scientifics Operating Income Related Terms

Thank you for viewing the detailed overview of Manhattan Scientifics's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Manhattan Scientifics (Manhattan Scientifics) Business Description

Traded in Other Exchanges
N/A
Address
244 Fifth Avenue, Suite 2341, New York, NY, USA, 10001
Manhattan Scientifics Inc is a company operating as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in the areas of nano-technologies and nano-medicines. The company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. The company is focused on technology transfer and commercialization of transformative technologies.
Executives
Chris Theoharis director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Photios Frank Georgiou director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Emmanuel Tsoupanarias director, officer: Chief Executive Officer 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Leonard Friedman director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Marvin Maslow director, 10 percent owner, officer: Chief Executive Office MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
David Teich director, officer: Treasurer MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
Ralph Anderson director 641 FIFTH AVENUE SUITE 36F, NEW YORK NY 10022
Larry H Schatz director 152 W. 57TH STREET, 31ST FLOOR, NEW YORK NY 10019
Marty Steinberg 10 percent owner 1111 BRICKELL AVENUE SUITE 2500, MIAMI FL 33131
Scott Bach director, officer: Secretary MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022

Manhattan Scientifics (Manhattan Scientifics) Headlines

No Headlines